ICU SeaStar Medical Holding Corporation

Subscribe to $ICU

SeaStar Medical Holding Corporation

Subscribe to $ICU

$ICU

Medical/Dental Instruments

Health Care

IPO Year: 2021

Exchange: NASDAQ

Recent Analyst Ratings for SeaStar Medical Holding Corporation

Date	Price Target	Rating	Analyst

See more ratings

SeaStar Medical Holding Corporation Press Releases

Fastest customizable press release news feed in the world

SeaStar Medical Reports Update on Nasdaq Listing Status
DENVER, June 25, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that it has undertaken a series of transactions to ensure compliance with Nasdaq's continued listing standards. Last year on June 24, 2024, SeaStar Medical received a written notification from Nasdaq's Listing Qualifications Staff that it was not in compliance with the requirement to maintain a minimum market value of listed securities of $35 million as required by Nasdaq Listing Rule 5550(b)(2). After a hearing before the Nasdaq Heari
6/25/25 8:05:00 AM ET
$ICU
Medical/Dental Instruments
Health Care
SeaStar Medical Announces Pricing of Up to $8 Million Public Offering
DENVER, June 20, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (the "Company" or "SeaStar Medical") (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, today announced the pricing of a public offering of 6,153,847 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and accompanying Series A warrants to purchase up to 6,153,847 shares of common stock and Series B short-term warrants to purchase up to 6,153,847 shares of common stock, at a combined offering price of $0.65 per share of common stock (or per pre-funded warrant in lieu thereof)
6/20/25 12:10:04 PM ET
$ICU
Medical/Dental Instruments
Health Care
AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical's SCD Therapy to Advance Breakthrough Burn and Sepsis Research
SAN ANTONIO, Texas and DENVER, Colorado, June 11, 2025 (GLOBE NEWSWIRE) -- The Autonomous Reanimation and Evacuation (AREVA) Research Institute and SeaStar Medical (NASDAQ:ICU) announced today that a new United States Department of Defense (DoD) grant has been awarded to AREVA. The grant is one of four selected out of 160 total submissions by the 2024 Military Burn Research Program (MBRP) and represents cutting-edge research for extracorporeal immunomodulation to reduce inflammation after severe burns, inhalation injury, and septicemia. The grant supports a three-year research study that is scheduled to begin in July 2025 with more than $2 million in DoD funding. The study will explore th
6/11/25 8:25:00 AM ET
$ICU
Medical/Dental Instruments
Health Care
SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy
Coverage marks SeaStar Medical's second award by CMS for reimbursement of medical expenses for Medicare and Medicaid patients in a clinical trial Stands out as rare award with less than 100 clinical trials covered annually DENVER, May 28, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that the U.S. Centers for Medicare & Medicaid Services (CMS) has agreed to pay for certain expenses incurred by medical centers treating patients covered by Medicare or Medicaid who are enrolled in the NEUTRALIZE-CRS
5/28/25 8:05:44 AM ET
$ICU
Medical/Dental Instruments
Health Care
SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates
QUELIMMUNE adoption drives four-fold increase in sequential quarter net revenue NEUTRALIZE AKI trial exceeds 50% enrollment, triggers start of Interim AnalysisWebcast Today at 4:30 pm Eastern Time DENVER, May 14, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months ended March 31, 2025, and provided business updates on key initiatives. "This is our second full quarter of the QUELIMMUNE launch and we believe our four-fold increase in revenue represents the strong comm
5/14/25 4:05:00 PM ET
$ICU
Medical/Dental Instruments
Health Care
SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury
DENVER, May 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it has successfully reached the halfway point in the NEUTRALIZE-AKI pivotal clinical trial, enabling a per protocol prespecified interim analysis by the trial's independent Data Safety Monitoring Review Board (DSMB). SeaStar Medical anticipates the DSMB will report its findings to the company in the third quarter of 2025. The NEUTRALIZE-AKI trial is evaluating the SCD therapy as a treatment for adult patients with Acute Kidney In
5/13/25 8:05:00 AM ET
$ICU
Medical/Dental Instruments
Health Care
SeaStar Medical to Report First Quarter Financial Results on May 14, 2025
DENVER, May 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, May 14, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, May 14, 2025, at 4:30 p.m. ET / 2:30 p.m. MTWebcast:The live webcast and replay can be found here.Conference ID:2078693Dial-in numbers:1 (800) 715-9871 within the U.S. 1 (646) 307-1963 from outside the U.S. A rep
5/7/25 10:00:00 AM ET
$ICU
Medical/Dental Instruments
Health Care
SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time
DENVER, April 30, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, CEO of SeaStar Medical, will be a featured guest today, Wednesday, April 30th, at approximately 10:50 am Eastern Time on the Benzinga All Access Show. The event will be broadcast live and can be viewed at https://youtube.com/live/ki1hFktn_2Y?feature=share. An archived recording of the presentation will be available on the investor relations section of the Sea Star Medical's website on the Events and Presentations pa
4/30/25 8:05:00 AM ET
$ICU
Medical/Dental Instruments
Health Care
FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery
DENVER, April 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that the U.S. Food and Drug Administration (FDA) has granted SeaStar Medical two new Breakthrough Device Designations for its Selective Cytopheretic Device (SCD) therapy. The two new Breakthrough Device Designations are indicated for the treatment of systemic inflammatory response in 1) adult patients undergoing cardiac surgery and 2) pediatric patients undergoing cardiac surgery towards prevention of post-operative adverse complicatio
4/8/25 8:05:00 AM ET
$ICU
Medical/Dental Instruments
Health Care
SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
DENVER, March 27, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and year ended December 31, 2024, and provided business updates on key initiatives. "Our significant accomplishment in 2024 position us well for a transformational year in 2025," said Eric Schlorff, SeaStar Medical CEO. "Last year, we not only received our first product approval for QUELIMMUNE and began our commercial launch, but we added 14 new clinical sites for our NEUTRALIZE AKI pivotal clinic
3/27/25 4:05:00 PM ET
$ICU
Medical/Dental Instruments
Health Care

SeaStar Medical Holding Corporation

Recent Analyst Ratings for SeaStar Medical Holding Corporation

SeaStar Medical Holding Corporation Press Releases

Fastest customizable press release news feed in the world

SeaStar Medical Reports Update on Nasdaq Listing Status

SeaStar Medical Announces Pricing of Up to $8 Million Public Offering

AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical's SCD Therapy to Advance Breakthrough Burn and Sepsis Research

SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy

SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates

SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury

SeaStar Medical to Report First Quarter Financial Results on May 14, 2025

SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time

FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery

SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

SeaStar Medical Holding Corporation SEC Filings

SEC Form SCHEDULE 13G filed by SeaStar Medical Holding Corporation

SEC Form 424B4 filed by SeaStar Medical Holding Corporation

SeaStar Medical Holding Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Other Events

SEC Form EFFECT filed by SeaStar Medical Holding Corporation

Amendment: SEC Form S-1/A filed by SeaStar Medical Holding Corporation

SEC Form S-1 filed by SeaStar Medical Holding Corporation

SeaStar Medical Holding Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

SEC Form 424B3 filed by SeaStar Medical Holding Corporation

SEC Form EFFECT filed by SeaStar Medical Holding Corporation

SEC Form S-1 filed by SeaStar Medical Holding Corporation

SeaStar Medical Holding Corporation Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Neuman John bought $14,396 worth of shares (40,000 units at $0.36), increasing direct ownership by 100% to 80,000 units (SEC Form 4)

Director Baird Jennifer A bought $12,815 worth of shares (10,000 units at $1.28) (SEC Form 4)

Chief Medical Officer Chung Kevin bought $5,625 worth of shares (4,500 units at $1.25), increasing direct ownership by 33% to 18,185 units (SEC Form 4)

SEC Form 4 filed by Chief Medical Officer Chung Kevin

SEC Form 4 filed by Chief Financial Officer Green David A

Director Neuman John bought $153,227 worth of shares (40,000 units at $3.83) (SEC Form 4)

SEC Form 3 filed by new insider Baird Jennifer A

SEC Form 4 filed by Director Baird Jennifer A

SEC Form 4 filed by Director Vincent Bernadette N

SEC Form 3 filed by new insider Vincent Bernadette N

SeaStar Medical Holding Corporation Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Neuman John bought $14,396 worth of shares (40,000 units at $0.36), increasing direct ownership by 100% to 80,000 units (SEC Form 4)

Director Baird Jennifer A bought $12,815 worth of shares (10,000 units at $1.28) (SEC Form 4)

Chief Medical Officer Chung Kevin bought $5,625 worth of shares (4,500 units at $1.25), increasing direct ownership by 33% to 18,185 units (SEC Form 4)

Director Neuman John bought $153,227 worth of shares (40,000 units at $3.83) (SEC Form 4)

Chief Medical Officer Chung Kevin bought $8,458 worth of shares (4,250 units at $1.99), increasing direct ownership by 45% to 13,685 units (SEC Form 4)

Chief Medical Officer Chung Kevin bought $4,258 worth of shares (1,000 units at $4.26), increasing direct ownership by 12% to 9,435 units (SEC Form 4)